Stemline Therap Drug Patent Portfolio
Stemline Therap owns 1 orange book drug protected by 8 US patents Given below is the list of Stemline Therap's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10385008 | Polymorphic forms of RAD1901-2HCL | 05 Jan, 2038 | Active |
US10745343 | Polymorphic forms of RAD1901-2HCl | 05 Jan, 2038 | Active |
US11819480 | Methods for treating cancer | 29 Nov, 2036 | Active |
US10071066 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
US10420734 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
US11779552 | Method of treating cancer using selective estrogen receptor modulators | 10 Oct, 2034 | Active |
US7612114 | Selective estrogen receptor modulator | 18 Aug, 2026 | Active |
US8399520 | Selective estrogen receptor modulator | 25 Dec, 2025 | Active |
Latest Legal Activities on Stemline Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Stemline Therap.
Activity | Date | Patent Number |
---|---|---|
Email Notification
Critical
| 09 Apr, 2024 | US11819480 |
Mail Pet Dec Routed to Certificate of Corrections Branch | 08 Apr, 2024 | US11819480 |
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 08 Apr, 2024 | US11819480 |
Adjustment of PTA Calculation by PTO | 05 Apr, 2024 | US11819480 |
Pet Dec Routed to Certificate of Corrections Branch | 05 Apr, 2024 | US11819480 |
Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 05 Apr, 2024 | US11819480 |
Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10071066 |
Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US8399520 |
Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US10420734 |
Second letter to regulating agency to determine regulatory review period | 08 Feb, 2024 | US7612114 |
Payment of Maintenance Fee, 4th Year, Large Entity | 31 Jan, 2024 | US10745343 |
Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US7612114 |
Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8399520 |
Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10071066 |
Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10420734 |
Stemline Therap's Family Patents
Stemline Therap Drug List
Given below is the complete list of Stemline Therap's drugs and the patents protecting them.
1. Orserdu
Orserdu is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10385008 | Polymorphic forms of RAD1901-2HCL |
05 Jan, 2038
(13 years from now)
| Active |
US10745343 | Polymorphic forms of RAD1901-2HCl |
05 Jan, 2038
(13 years from now)
| Active |
US11819480 | Methods for treating cancer |
29 Nov, 2036
(11 years from now)
| Active |
US10071066 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(9 years from now)
| Active |
US10420734 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(9 years from now)
| Active |
US11779552 | Method of treating cancer using selective estrogen receptor modulators |
10 Oct, 2034
(9 years from now)
| Active |
US7612114 | Selective estrogen receptor modulator |
18 Aug, 2026
(1 year, 7 months from now)
| Active |
US8399520 | Selective estrogen receptor modulator |
25 Dec, 2025
(1 year, 6 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orserdu's drug page